Skip to main content
    G

    Gilead Sciences Inc (GILD)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $167.58
    -0.50 (-0.30%)

    Market Cap: $208.48B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Gilead Sciences Inc (GILD) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Gilead Sciences (GILD) trades at 6.7x sales and 16.0x book value. Its P/S of 6.7x is above its 5-year median of 3.8x. Its forward P/E is 16.8x.

    Current Multiples

    Its enterprise value is 176.3x its EBITDA. Its free cash flow yield is 6.6%.

    MultipleValue
    P/E (trailing)N/A
    Forward P/E16.8x
    Price to sales6.7x
    Price to book16.0x
    EV/EBITDA176.3x
    Price to FCF15.1x
    EV/FCF16.5x
    PEGN/A
    FCF yield6.6%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 81.1% above 3.7x and its P/B is 255.6% above 4.5x.

    MultipleCurrent5-year median10-year median
    P/EN/A13.6x10.0x
    P/S6.7x3.8x3.7x
    P/B16.0x5.1x4.5x
    Medians of month-end values through Oct 2026: 55 to 60 months (5-year) and 115 to 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 6.2x in 2016 to 20.0x in 2024.

    Year endPriceP/EP/SP/B
    2025$122.7415.1x5.2x6.8x
    2024$92.3720.0x4.0x6.0x
    2023$81.0112.1x3.7x4.5x
    2022$85.8511.8x4.0x5.1x
    2021$72.6110.0x3.3x4.3x
    2020$58.268.2x3.0x4.0x
    2019$64.989.8x3.7x3.7x
    2018$62.559.4x3.7x3.8x
    2017$71.648.1x3.6x4.6x
    2016$71.616.2x3.2x4.9x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About GILD

    What is GILD's forward P/E ratio?

    Gilead Sciences has a forward P/E ratio of 16.8x.

    Is GILD stock overvalued?

    GNG's valuation label for GILD is Overvalued.

    What is GILD's price to sales ratio?

    Gilead Sciences has a price to sales ratio of 6.7x.

    What is Gilead Sciences's average P/E ratio over 5 years?

    Gilead Sciences's median P/E over the last 5 years is 13.6x, from 55 month-end values through Oct 2026.